Big effect
In a small but rigorous trial, 3 g/day L-carnitine cut 28-day mortality by more than half in septic ICU patients — but prior studies found no benefit, so the picture is far from settled.
This single randomized trial found a strikingly large reduction in death among critically ill septic patients given L-carnitine, but because only 60 people were studied and two out of three earlier trials saw no effect, this result is an intriguing signal, not a proven therapy.
In a double-blind, placebo-controlled trial of 60 critically ill patients with sepsis, those who received 3 g/day of L-carnitine had a 28-day mortality rate of 7 deaths versus 15 in the placebo group — a statistically significant difference (odds ratio 0.233, p = 0.010). The supplement also lowered markers of inflammation (CRP, ESR) and boosted antioxidant defenses (SOD, TAC). However, the overall body of evidence on L-carnitine for mortality is still weak and mixed, so this finding needs replication before drawing firm conclusions.
Where this fits in the evidence
Pillser has synthesized 4 studies on L-Carnitine for Reduced Mortality Rate — overall evidence strength: Low.
Evidence from 4 clinical studies (2 meta-analyses and 2 RCTs) shows mixed effects of L-carnitine supplementation on mortality rate. Two studies reported large beneficial effects in critically ill septic patients and individuals with acute aluminum phosphide poisoning, while two meta-analyses found no statistically significant effect on mortality. The predominant effect size across beneficial studies was large, but the median study duration was 186 days (approximately 6 months), and the most-studied population was clinical patients with sepsis or septic shock.
The study
- Randomized Controlled Trial (RCT)
- n = 60
- 2024-03-06
- Nutrition journal
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.